Why is a life-changing Alzheimer's disease treatment certified in Europe but not here in the U.S.?
Join thousands of Americans urging the FDA to approve Cerezen™ for treating Alzheimer’s disease.
Add your name and story to our formal petition and we’ll deliver it to your U.S. Representative and the FDA.
By submitting this form, you authorize Renew GPL to transmit your comments, name, and location to the FDA and your U.S. Representative. Do not include sensitive medical details (such as SSNs or specific account numbers) that you do not wish to be public.
Cerezen has been certified under EU MDR 2017/745 for the treatment of mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease.
In the United States, it was designated a Breakthrough Device by the FDA in 2021, but still has not been fully approved.
After Cerezen was approved in October 2025 in the EU for the treatment of Alzheimer’s disease, CEO and Founder of Cerezen, Manoj Bhargava, wrote to the FDA Commissioner asking to review and approve it here in the United States. No response…
